Loading…
Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.
Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.
Has no approved product and no sales; funding comes from raising capital, and everything rides on one drug, lorundrostat, through late-stage trials and regulatory review. Hypertension is dominated by cheap generics, so a new pill must earn its place with doctors and insurers.
Moat: none (IP / patents). Differentiated aldosterone synthase mechanism but competes directly with a similar AstraZeneca candidate.
Headquarters: Radnor, Pennsylvania, US · Founded: 2018 · Employees: 76
Size Mineralys Therapeutics (MLYS) is a United States Health Care company (Biotechnology) with a market value of $1.36B, the 2060th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.33 on 6 Nov 2026.
Performance Over six months the shares fell 48.1%, against -15.8% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Short interest Short interest is 8.4% of the free float (15 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$39,000 | -$59,000 | -$43,000 | $0 | $0 |
| EBITDA | -$371M | -$171M | -$192M | -$84.7M | -$31.5M |
| Net income | -$350M | -$155M | -$178M | -$71.9M | -$29.8M |
| Free cash flow | -$139M | -$142M | -$166M | -$81.2M | -$29.2M |
| Capital expenditure | $15,000 | $15,000 | $96,000 | $0 | $0 |
| Total debt | $97.6M | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics MLYS | $1.36B | -48% | n/a | n/a | n/a | n/a |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
| Idorsia IDIA.SW | $1.34B | -5% | -5% | -70% | 10.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MLYS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.5% | -1.7% | 3rd lowest of 21 |
| 6-month return | -48.1% | -15.8% | 2nd lowest of 20 |
| Distance from 52-week high | -67.8% | -41.7% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |